36.4. The Potential Double Duty of ISR Inhibitors in AD Therapy: (1) Disabling the AβPP-Independent iAβ Generation Pathway and (2) Enabling the Production of BACE1 and BACE2. This evidence concerns the gene APP and Alzheimer disease.